ArticleCirculation. Heart failure2012
Multiple biomarkers for risk prediction in chronic heart failure.
Article in Circulation. Heart failure, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 202 citations in OpenAlex.
- Prognostic models in populations with heart failure: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis.Heart failure reviews · 2022Pooled it
- T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.Clinical research in cardiology : official journal of the German Cardiac Society · 2019Trial
- Identifying biomarker patterns and predictors of inflammation and myocardial stress.Journal of cardiac failure · 2015Trial
- Trial
- Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.Circulation. Heart failure · 2013Trial
- Predictive value of hematological parameters in prognosis of congestive heart failure patients in a tertiary hospital, Addis Ababa, Ethiopia.BMC cardiovascular disorders · 2025Article
- Natriuretic peptides testing and survival prediction models for chronic heart failure: a systematic review of added prognostic value.Diagnostic and prognostic research · 2025Review
- Association of MPO levels with cardiometabolic disease stratified by atherosclerotic cardiovascular risk and intensity of therapy in a workforce population.Scientific reports · 2025Article
- Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations.Circulation. Heart failure · 2025Article
- Prediction models and risk scores in different types of heart failure: a review.Frontiers in medicine · 2025Review
- Myocardial Recovery and Relapse in Heart Failure With Improved Ejection Fraction.Current treatment options in cardiovascular medicine · 2024Article
- Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure.Biomolecules · 2024Review
- Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2024Article
- Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults.GeroScience · 2022Article
- Prioritization of Candidate Biomarkers for Degenerative Aortic Stenosis through a Systems Biology-Based In-Silico Approach.Journal of personalized medicine · 2022Article
- Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design.International journal of heart failure · 2022Review
- Oxidative stress markers-driven prognostic model to predict post-discharge mortality in heart failure with reduced ejection fraction.Frontiers in cardiovascular medicine · 2022Article
- Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.Journal of geriatric cardiology : JGC · 2021Article
- Predicting clinical events using Bayesian multivariate linear mixed models with application to scleroderma.BMC medical research methodology · 2021Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPrior studies have suggested using a panel of biomarkers that measure diverse biological processes as a prognostic tool in chronic heart failure. Whether this approach improves risk prediction beyond clinical evaluation is unknown. METHODS AND
resultsIn a multicenter cohort of 1513 chronic systolic heart failure patients, we measured a contemporary biomarker panel consisting of high-sensitivity C-reactive protein, myeloperoxidase, B-type natriuretic peptide, soluble fms-like tyrosine kinase receptor-1, troponin I, soluble toll-like receptor-2, creatinine, and uric acid. From this panel, we calculated a parsimonious multimarker score and assessed its performance in predicting risk of death, cardiac transplantation, or ventricular assist device placement in comparison to an established clinical risk score, the Seattle Heart Failure Model (SHFM). During a median follow-up of 2.5 years, there were 317 outcomes: 187 patients died; 99 were transplanted; and 31 had a ventricular assist device placed. In unadjusted Cox models, patients in the highest tertile of the multimarker score had a 13.7-fold increased risk of adverse outcomes compared with the lowest tertile (95% confidence interval, 8.75-21.5). These effects were independent of the SHFM (adjusted hazard ratio, 6.80; 95% confidence interval, 4.18-11.1). Addition of the multimarker score to the SHFM led to a significantly improved area under the receiver operating characteristic curve of 0.803 versus 0.756 (P=0.003) and appropriately reclassified a significant number of patients who had the outcome into a higher risk category (net reclassification improvement, 25.2%; 95% confidence interval, 14.2-36.2%; P<0.001).
conclusionsIn ambulatory chronic heart failure patients, a score derived from multiple biomarkers integrating diverse biological pathways substantially improves prediction of adverse events beyond current metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.